

Göttingen, Germany | Alès, France | June 23, 2026

## Sartorius and LFB BIOMANUFACTURING strengthen collaboration

- Sartorius and LFB BIOMANUFACTURING will collaborate to offer an integrated solution.
- Clients will benefit from collaboration and coordinated timelines that provide a streamlined and seamless path from cell line development (CLD) to the clinic
- The companies will de-risk and accelerate development for clients by combining proven expertise and capabilities

Sartorius and LFB BIOMANUFACTURING have announced an expansion of their collaboration with the aim of offering biopharmaceutical clients a comprehensive CLD to first batch of GMP drug substance service. The collaboration is designed to simplify and accelerate the path to the clinic. Building on their successful collaboration launched in March 2024, this step will combine Sartorius expertise in CLD and master cell bank manufacturing with capabilities from LFB BIOMANUFACTURING, including upstream and downstream process development, analytical development and testing, and GMP drug substance manufacturing. Together, the collaboration enables Sartorius and LFB BIOMANUFACTURING to gain access to each other's respective platforms and technologies to offer a single path to the clinics.

"Our clients are at the center of this collaboration," said Stefan Northoff, Head of Cell Line, Media, and Testing Solutions at Sartorius. "By collaborating with LFB BIOMANUFACTURING, we combine our cutting-edge CLD technology, including our recently launched genetically engineered host cell line, with expertise from LFB BIOMANUFACTURING in manufacturing, to help our clients achieve success as they take their therapeutics seamlessly to the clinic."

"Through the strengthened collaboration between Sartorius and LFB BIOMANUFACTURING, our clients will gain access to a powerful combination of expertise spanning CLD, process optimization, and manufacturing," said Herbert Guedegbe, Managing Director of LFB BIOMANUFACTURING. "This will enable our clients to move their innovative drug development programs forward with greater confidence and speed while improving patient outcomes."

LFB BIOMANUFACTURING is a recognized CDMO with extensive experience developing therapeutic proteins, including monoclonal antibodies, Fc-fusions, bispecifics, and other complex biologics. Sartorius brings more than 15 years of commercial CLD experience, having completed more than 330 projects, with more than 85 programs advancing into clinical development and over 10 achieving market approval.

The expanded collaboration reflects both companies' long-term commitment to supporting biologics innovators with integrated, high-quality development solutions. By building on proven synergies established through multiple successful projects, Sartorius and LFB BIOMANUFACTURING are creating a framework to support the next generation of therapeutic innovation.

### More information about CHO CLD Services:

[Cell Line Development Services | Sartorius](#)

### A profile of Sartorius

Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2025, the company generated sales revenue of around 3.4 billion euros. More than 14,000 employees work for customers around the globe.

Visit our [Newsroom](#) or follow us on [LinkedIn](#).

### A profile of LFB BIOMANUFACTURING

LFB BIOMANUFACTURING, one of the key entities in the LFB group's bioproduction activities, operates the Alès (Gard department) industrial site specializing in the manufacture of recombinant medicinal products by cell culture, and of recombinant proteins and monoclonal antibodies in particular.

LFB BIOMANUFACTURING acts as a CDMO to offer its customers bioproduction services ranging from the development of cell lines to the manufacture of recombinant medicinal products compliant with GMP standards. At its FDA-approved industrial site in Alès, LFB BIOMANUFACTURING manufactures a recombinant coagulation factor for the LFB group, as well as clinical and commercial batches on behalf of third parties.

For more information about LFB BIOMANUFACTURING, go to <https://www.lfbbiomanufacturing.com>  
Connect with LFB BIOMANUFACTURING via [LinkedIn](#)

### A profile of LFB

LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases. Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care. LFB's current market portfolio includes 15 biomedicinal products sold in about 30 countries.

### Contact Sartorius

Lars Hanf  
Head of Marketing BPS  
[lars.hanf@sartorius.com](mailto:lars.hanf@sartorius.com)  
+49 175 955 8820

**Contact LFB BIOMANUFACTURING**

Vincent Dehousse  
Head of Business Development  
[vincent.dehousse@lfb.fr](mailto:vincent.dehousse@lfb.fr)  
+32 473 750 870